Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Performance of Alzheimer Disease Plasma Biomarkers in Patients With Prion Diseases.

Neurology·2026

Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026

Same author

ChatGPT in the diagnosis and management of complex polyneuropathies: comparative analysis with neurologists using real-world cases.

NPJ digital medicine·2026

Same author

Acquired vitamin B6 deficiency in POEMS: a marker of disease activity and cause of neuropathy?

Journal of neurology, neurosurgery, and psychiatry·2026

Same author

Front-line systemic treatment outcomes in POEMS syndrome.

British journal of haematology·2026

Same author

Heterogeneous Activated B Cell Compartments Arising Early and Transiently After SARS-CoV-2 Vaccination.

European journal of immunology·2026

Search research articles

Related Experiment Video

Updated: Jun 11, 2025

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

Novel therapies in CIDP.

Devan Mair^1,2, Heba Madi¹, Filip Eftimov³

¹Barts Health NHS Trust, London, UK.

Journal of Neurology, Neurosurgery, and Psychiatry

|October 2, 2024

Summary

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder with limited treatment options. This review explores CIDP

Keywords:

IMMUNOLOGY NEUROIMMUNOLOGY NEUROMUSCULAR NEUROPATHY

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Experiment Videos

Last Updated: Jun 11, 2025

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

In Vitro Myelination of Peripheral Axons in a Coculture of Rat Dorsal Root Ganglion Explants and Schwann Cells

Published on: February 10, 2023

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Area of Science:

Neurology
Immunology
Pathogenesis

Background:

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous immune-mediated neurological disorder.
Current first-line treatments like steroids, IVIG, and plasma exchange benefit approximately two-thirds of patients but rarely achieve complete remission.
Existing therapies present significant practical, financial, and medical challenges.

Purpose of the Study:

To detail the key pathogenic mechanisms underlying CIDP.
To provide an in-depth description of novel therapeutic strategies for CIDP.
To review the current evidence for these emerging therapies in clinical practice.

Main Methods:

This narrative review synthesizes existing literature on CIDP pathogenesis and novel treatments.
It focuses on immunological mechanisms and their therapeutic implications.
Evidence for novel therapies is evaluated based on current clinical practice.

Main Results:

CIDP pathogenesis involves complex, not fully understood immunological mechanisms.
Novel targeted therapeutics show promise for autoimmune neurological disorders, including CIDP.
The review highlights the potential of new treatments to overcome limitations of current therapies.

Conclusions:

Understanding CIDP's immunological basis is crucial for developing effective treatments.
Novel targeted therapies represent a promising advancement in managing CIDP.
Further research and clinical trials are needed to establish the efficacy and safety of new CIDP treatments.